Las Vegas--A single application of cooled transurethral microwavetherapy led to clinically and statistically significant symptom improvementin a pilot study involving patients with intractable chronic prostatitis,accompanied by BPH in some cases.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.